Vehicles of Drug Delivery and Biomarkers in Multiple Sclerosis



Suhayl Dhib-Jalbut Professor and Chairman, Neurology

CURRENT RESEARCH

Understanding mechanisms of multiple sclerosis to develop novel therapeutic approaches and identify biomarkers of treatment responses

According to recent statistics, more than 400,000 people in the United States are diagnosed with multiple sclerosis (MS), and about 200 new cases are diagnosed each week. Currently MS therapies are very expensive, as choosing therapy for a particular patient is a trial and error process. Dr. Suhayl Dhib-Jalbut, Professor and Chairman of Neurology at Rutgers Biomedical and Health Sciences, is studying underlying mechanisms of neurodegeneration in MS, testing novel neuroprotective approaches, and identifying biomarkers of treatment response. A predictive biomarker of treatment response can help choose the correct medication that patients are most likely to respond to, and save patients and payors

MS is an inflammatory demyelinating and degenerative disease of the central nervous system (CNS), whose response to immune-based therapies declines as the disease progresses. In order to develop effective treatments, it is critical to elucidate the underlying mechanisms of neurodegeneration in MS and identify biomarkers that will help determine the $\ensuremath{^{\circ}}$ effectiveness of medication early into treatment and illuminate the best therapeutics for each patient. Several MS centers, including centers at University of Maryland, Baltimore and Carolinas HealthCare System in North Carolina, have collaborated with Dr. Dhib-Jalbut in the biomarker study, to identify candidate biomarkers for a few drugs in the market. Currently, Dr Dhib-Jalbut hopes to validate these biomarkers in animal models as well as human peripheral mononuclear blood cells, and investigate novel ways to deliver therapeutics.

Dr. Dhib.

AFFILIATION



Rutgers University

EDUCATION

- Neuroimmunology and Multiple Sclerosis Fellowship in 1990, National Institute of Health
- Neurology Residency in 1985, University of Cincinnati
- M.D. in 1980, American University of Beirut

AWARDS

- National Institutes of Health Mid-career Investigator Award
- President, Americas Committee for Treatment and Research in MS (ACTRIMS)
- Norman Edelman Clinical Science Mentoring Award
- New Jersey Health Foundation Award for excellence in clinical research

RESEARCH AREAS

Life Science, Immunology / Inflammatory, Neurological / Cognitive, Neurological /

FUNDING REQUEST

Your contributions will support the continued research of Dr. Suhayl Dhib-Jalbut of Rutgers University as he tests novel therapeutic approaches and identifies biomarkers for more effective treatment in multiple sclerosis. Donations will help fund the \$250K/year required for personnel, material, and equipment, particularly technicians and reagents to conduct experiments. Help bring effective solutions to MS patients by partnering with Dr. Dhib-Jalbut.

 $\label{lem:compright} \ @\ 2017 / \ Benefunder\ 4790\ Eastgate\ Mall,\ Ste\ 125.\ San\ Diego,\ CA\ 92121\ /\ info@benefunder.com\ /\ (858)\ 215-1136$